CYV.AU Ceryvyn Therapeutics Limited

Healthcare Biotechnology Australian Securities Exchange
0.0100 AUD
Close of Nov 1, 2026
0.0080 0.6000
Market cap
AUD 13.7M
P/E
0.0x
P/B
0.46x
ROE
1,115.8%
Dividend yield
-
Fundamental score
1.8/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CYV.AU undervalued?

Graham number

The Graham number of Ceryvyn Therapeutics Limited cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ceryvyn Therapeutics Limited fundamental analysis

9 of 22 checks passed

ROE 2/2

High return on equity (1,115.8%), above 20%.

ROA 1/1

Return on assets (1,034.8%) is above the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Earnings growth cannot be compared with the industry.

Revenue Growth 0/2

Revenue shrank 81.7% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 30.9x against interest expense, well covered.

PE vs Market 1/1

PE (0.0x) is below the market median (15.0x).

PE vs Industry 1/1

PE (0.0x) is below the industry median (16.3x).

PBV 1/1

Price to book (0.5x) is below the industry median (4.4x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 0.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Ceryvyn Therapeutics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ceryvyn Therapeutics Limited

Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was i…

Full company profile